Holen Sie sich die Stockscreener-App
1.22
3.39%
0.04
Handel nachbörslich:
1.22
Schlusskurs vom Vortag:
$1.18
Offen:
$1.18
24-Stunden-Volumen:
972.63K
Relative Volume:
0.75
Marktkapitalisierung:
$151.89M
Einnahmen:
$1.78M
Nettoeinkommen (Verlust:
$-68.36M
KGV:
-1.7868
EPS:
-0.6828
Netto-Cashflow:
$-51.59M
1W Leistung:
+9.91%
1M Leistung:
-5.43%
6M Leistung:
-30.68%
1J Leistung:
-19.21%
1-Tages-Spanne:
$1.16
$1.22
1-Wochen-Bereich:
$1.08
$1.22
52-Wochen-Spanne:
$1.00
$3.06
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Firmenname
Milestone Pharmaceuticals Inc
Sektor
Branche
Telefon
(514) 336-0444
Adresse
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.22 | 140.68M | 1.78M | -68.36M | -51.59M | -0.6828 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Raymond James | Strong Buy |
| 2025-12-15 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-09-11 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-08-22 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-06-20 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-22 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-29 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-07-24 | Hochstufung | Jefferies | Hold → Buy |
| 2020-03-25 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-03-24 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-03 | Eingeleitet | Cowen | Outperform |
| 2019-06-03 | Eingeleitet | Jefferies | Buy |
| 2019-06-03 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Milestone Pharmaceuticals Inc Aktie (MIST) Neueste Nachrichten
Milestone Pharmaceuticals Inc (MIST) Cash Flow - TradingKey
Milestone Pharmaceuticals Inc (MIST) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MIST|Milestone Pharmaceuticals Inc|Price:1.160|Chg%:-0.040 - TradingKey
TradingKey - TradingKey
Milestone Pharmaceuticals (MIST) Declines 3.33% as Stock Tests Key Support at $1.10Median Line - dars.gov.et
Milestone Pharmaceuticals Inc. Revenue Breakdown – NASDAQ:MIST - TradingView
Milestone Pharmaceuticals Inc (MIST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Wells Fargo Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Cuts Target Price to $7 - Moomoo
Milestone Pharmaceuticals (MIST) Q4 2024 earnings summary - Quartr
Price to book forward of Milestone Pharmaceuticals Inc. – NASDAQ:MIST - TradingView
Milestone Pharmaceuticals Inc (MIST) Institutional Confidence - TradingKey
Milestone Pharmaceuticals (MIST) Investor update Summary - Quartr
Heart Rhythm Society and Milestone Pharmaceuticals Partner to Expand SVT Patient Education Through UpBeat.org - AOL.com
Milestone Pharmaceuticals (MIST) Slips 2.3% as Shares Test Key Support LevelsBuy Signal Reports - DonanımHaber
Milestone lures six new employees with 288,000 options - Stock Titan
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Enterprise value to EBIT forward of Milestone Pharmaceuticals Inc. – NASDAQ:MIST - TradingView
Enterprise value to EBIT forward of Milestone Pharmaceuticals Inc. – BOATS:MIST - TradingView
Price to sales forward of Milestone Pharmaceuticals Inc. – NASDAQ:MIST - TradingView
Price to sales forward of Milestone Pharmaceuticals Inc. – BOATS:MIST - TradingView
Enterprise value to EBITDA forward of Milestone Pharmaceuticals Inc. – NASDAQ:MIST - TradingView
Enterprise value to revenue forward of Milestone Pharmaceuticals Inc. – BOATS:MIST - TradingView
Price to earnings forward of Milestone Pharmaceuticals Inc. – BOATS:MIST - TradingView
Milestone Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:MIST) - TradingView
MIST Forecast — Price Target — Prediction for 2027 - TradingView
Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762 - TMX Newsfile
Milestone Pharmaceuticals StockSunday background on the cardiac drug developer - AD HOC NEWS
Milestone Pharmaceuticals Inc (MIST) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Milestone Pharmaceuticals Inc - TradingKey
Milestone Pharmaceuticals Inc (MIST) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Milestone Pharmaceuticals Inc (MIST) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Milestone Pharmaceuticals Inc (MIST) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Milestone Pharmaceuticals Inc (MIST) Valuation: PE, PB & Fair Value Analysis - TradingKey
Milestone Pharmaceuticals (MIST) Climbs Over 5%: Biotech Stock Breaks Above Key Support ZoneDebt Free Companies - dars.gov.et
Milestone Pharmaceuticals Shareholders Approve Governance and Compensation Measures - The Globe and Mail
Milestone Pharmaceuticals Faces Financial Challenges amidst Market Shifts - timothysykes.com
Milestone Pharmaceuticals (MIST) investors approve equity plan, elect board and ratify PwC - Stock Titan
Milestone (NASDAQ: MIST) director receives 77,000 stock options grant - Stock Titan
Milestone Pharmaceuticals (MIST) director receives 77,000 stock options at $1.22 strike - Stock Titan
Milestone Pharmaceuticals (MIST) awards director 77,000 stock options - Stock Titan
Milestone Pharmaceuticals (MIST) director receives 77,000 stock options at $1.22 - Stock Titan
Director at Milestone Pharmaceuticals (MIST) receives 77,000 stock options at $1.22 - Stock Titan
Milestone Pharmaceuticals (NASDAQ: MIST) director receives 77,000 stock options grant - Stock Titan
Milestone Pharmaceuticals (MIST) director receives grant of 77,000 stock options - Stock Titan
Milestone Pharmaceuticals: Here Comes The Revenue Ramp (NASDAQ:MIST) - Seeking Alpha
Milestone Pharmaceuticals (MIST) Q1 2026 Earnings: Narrowing Losses as Clinical Progress ContinuesCost Structure Review - dars.gov.et
Novartis Canada and the pan-Canadian Pharmaceutical Alliance Achieve Milestone Agreement Enabling Public Reimbursement of (pr)Scemblix® (asciminib tablets) - Newswire Canada
Milestone Pharmaceuticals: Taking The Long View (NASDAQ:MIST) - Seeking Alpha
Eli Lilly scores a first in major pharma milestone - thestreet.com
Wockhardt's Zaynich wins US FDA approval, marking milestone in antibiotic innovation - Business Today
Milestone (MIST) Q1 2026 Earnings Transcript - The Globe and Mail
Finanzdaten der Milestone Pharmaceuticals Inc-Aktie (MIST)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.84%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):